NovoCure Valuation
Is N2VC34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of N2VC34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: N2VC34 (R$9.61) is trading below our estimate of fair value (R$25.49)
Significantly Below Fair Value: N2VC34 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for N2VC34?
Key metric: As N2VC34 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is N2VC34's PS Ratio? | |
|---|---|
| PS Ratio | 3.5x |
| Sales | US$577.74m |
| Market Cap | US$2.03b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3x |
| Enterprise Value/EBITDA | -12.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does N2VC34's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.4x | ||
ODPV3 Odontoprev | 2.5x | 3.4% | R$5.9b |
FLRY3 Fleury | 1x | 6.5% | R$7.4b |
HAPV3 Hapvida Participações e Investimentos | 0.8x | 7.4% | R$22.3b |
IART Integra LifeSciences Holdings | 1.2x | 5.8% | US$1.8b |
N2VC34 NovoCure | 3.5x | 9.4% | R$2.0b |
Price-To-Sales vs Peers: N2VC34 is expensive based on its Price-To-Sales Ratio (3.5x) compared to the peer average (1.4x).
Price to Sales Ratio vs Industry
How does N2VC34's PS Ratio compare vs other companies in the Global Medical Equipment Industry?
| 134 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 134 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: N2VC34 is expensive based on its Price-To-Sales Ratio (3.5x) compared to the Global Medical Equipment industry average (3.3x).
Price to Sales Ratio vs Fair Ratio
What is N2VC34's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate N2VC34's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Teladoc Health
US$1.8b
Provides virtual healthcare services worldwide.
T2DH34
US$2.38
7D
35.2%
1Y
-15.9%
CVS Health
US$73.0b
Provides health solutions in the United States.
CVSH34
US$34.61
7D
7.0%
1Y
2.1%
Koninklijke Philips
€24.2b
Operates as a health technology company in North America, the Greater China, and internationally.
PHGN34
€152.70
7D
2.0%
1Y
n/a